Bispecific antibodies are recognized as artificial protein where two
or more antigen recognizing elements are combining together to form a
single construct. Bispecific antibodies are able to bind into two or
more targets at a time. Moreover, these antibodies might bridge two
targets together and are able to present high chances of gaining
therapeutic effects (bring cancer cell within striking distance). The
various formats of bispecific antibodies include quadromas, chemical
heteroconjugates, bispecific antibodies with special
heterodimeriza-tion domains and bispecific antibodies of minimal
size. Bispecific antibodies are primarily utilized for the treatment
of cancer and are emerging as a novel technology for dual targeting
strategies within one molecule for cancer treatment. Bispecific
antibodies improve and ensure the following factors in a cancer
targeting agent: increase binding ability, improve selectivity and
efficacy. It has observed that bispecific antibodies provide improved
efficacy for cancer treatment as compared with combination therapy of
other two antibodies. Recombinant DNA technology is identified as the
backbone of rapid expansion of bispecific antibody formats.
Bispecific antibodies are evolving a the most preferred and efficient
method of treatment for various cancer such as breast, lung, prostate
and colon cancer. With rising prevalence of different types of cancer
(lung cancer, breast cancer and cervical cancer) the global market
for bispecific antibodies treatment is significantly increasing. The
World Health Organization (WHO) published in 2014, that worldwide 8.2
million people died of cancer in 2012. Likewise, American Cancer
Society (ACS) published that, around 300,000 men and 276,000 women
died due to cancer in 2012 in the U.S. Moreover, it is observed that
of every six U.S. men have received a diagnosis test for prostate
cancer at some point in their lives stated by California Journal of
Clinical Cancer (CJCC). However, technical complexity associated with
the treatment procedure (detection) of bispecific antibodies would
hinder the global market demand of bispecific antibodies treatment
during the study period.
North America and Europe were observed to be the largest bispecific
antibodies treatment market due to major market players are based in
these regions. Moreover, it has observed that the highest numbers of
various cancers (lung cancer, prostate cancer, breast cancer and
cervical cancer) diagnosis cases are recorded from North America and
Europe every year. In addition, favorable initiatives taken by the
federal government also would be accounted for the market growth of
bispecific antibodies treatment in North American and European
regions.
Download Report Brochure @
https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=7331
Similarly, Asia-Pacific is considered as an untapped market in
bispecific antibodies treatment due to lack of proper healthcare
facilities in some Asian countries. Asian market growth will be
fuelled by the presence of untapped opportunities due to extensive
increase in the healthcare infrastructure (healthcare cost,
healthcare facility and health care budget). Similarly, Asia-Pacific
is considered as an emerging market in bispecific antibodies
treatment due to growing market penetration in this region. The rest
of the world (RoW) holds fourth position in the global bispecific
antibodies treatment market due to poor economic and health condition
in most of the African countries. It has also observed that
bispecific antibodies market growth in RoW will be fuelled primarily
by extensive increase in healthcare infrastructure in Brazil and
Mexico.
Some of the major players operating in the bispecific antibodies
treatment market includes AbbVie, Celgene, Ganymed Pharmaceuticals,
Janssen Biotech, OncoMed Pharmaceuticals, Paktis Antibody Services
GmbH, Fabion Pharmaceuticals among others.
Pre-Book Full Report @
https://www.transparencymarketresearch.com/checkout.php?rep_id=7331<ype=S
About Us
Transparency Market Research (TMR) is a market intelligence company,
providing global business information reports and services. Our
exclusive blend of quantitative forecasting and trends analysis
provides forward-looking insight for thousands of decision makers.
TMR’s experienced team of analysts, researchers, and consultants,
use proprietary data sources and various tools and techniques to
gather, and analyze information. Our business offerings represent the
latest and the most reliable information indispensable for businesses
to sustain a competitive edge.
Each TMR syndicated research report covers a different sector - such
as pharmaceuticals, chemicals, energy, food & beverages,
semiconductors, med-devices, consumer goods and technology. These
reports provide in-depth analysis and deep segmentation to possible
micro levels. With wider scope and stratified research methodology,
TMR’s syndicated reports strive to provide clients to serve their
overall research requirement.
US Office
Contact
90 State Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453
Email:
sales@transparencymarketresearch.com
No comments:
Post a Comment